NCT05296655

Brief Summary

Reflux symptoms index (RSI) were developed to identify a clinical index of suspicion for laryngopharyngeal reflux (LPR) in patients with ear, nose, and throat symptoms. RSI is an efficient diagnostic tool for LPR/ It is easy to use, even for those who know little about LPR. It does not require special equipment or examinations and is inexpensive. Thus, it can be considered highly efficient and cost-effective. The study will focus on translating and testing the RSI into Kazakh language and comparing its results in healthy people and people with laryngopharyngeal reflux.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
248

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2020

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2022

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 16, 2022

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

March 17, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 25, 2022

Completed
Last Updated

May 23, 2022

Status Verified

May 1, 2022

Enrollment Period

2 years

First QC Date

March 17, 2022

Last Update Submit

May 17, 2022

Conditions

Keywords

Laryngopharyngeal RefluxLaryngopharyngeal Reflux SymptomsLaryngitisLaryngopharyngitis ChronicGastro Esophageal Reflux

Outcome Measures

Primary Outcomes (10)

  • RSI Score at Baseline:

    Patients will be asked to complete the Reflux Symptom Index questionnaire. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. The severity of the problem is calculated as the summation of all points. The problem is absent if the summation of points is 0. The problem is serious if the summation of points is 5. Total score ranges from 0-45; of which 0-12 is considered no laryngopharengeal reflux, above 13 points for the presence of laryngopharyngeal reflux.

    RSI Score at Baseline

  • RSI Score at Days 10-14

    Patients will be asked to complete the Reflux Symptom Index questionnaire. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. The severity of the problem is calculated as the summation of all points. The problem is absent if the summation of points is 0. The problem is serious if the summation of points is 5. Total score ranges from 0-45; of which 0-12 is considered no laryngopharengeal reflux, above 13 points for the presence of laryngopharyngeal reflux.

    Days 10-14

  • RFS Score at Baseline:

    Device: Endoscopic laryngoscopy Video laryngoscopy and assessment of the presence / severity of the symptoms- Reflux finding score. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem. Total score ranges from 0-48; of which 0-6 is considered no laryngopharengeal reflux, above 7 points for the presence of laryngopharyngeal reflux.

    RFS Score at Baseline

  • RFS Score at Days 10-14

    Device: Endoscopic laryngoscopy Video laryngoscopy and assessment of the presence / severity of the symptoms - Reflux finding score and will be used as a gold standard of diagnosis of laryngopharengeal reflux. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem. Total score ranges from 0-48; of which 0-6 is considered no laryngopharengeal reflux, above 7 points for the presence of laryngopharyngeal reflux.

    Days 10-14

  • Reliability and validity of RSI at Baseline:

    Reliability and validity of RSI at Baseline using Cronbach's alpha test to check the internal consistency for all the 9 items. Total score ranges from 0-45; of which 0-12 is considered no laryngopharengeal reflux, above 13 points for the presence of laryngopharyngeal reflux.

    RSI Score at Baseline

  • Reliability and validity of RSI at Days 10-14.

    Reliability and validity of RSI at Days 10-14 using Cronbach's alpha test to check the internal consistency for all the 9 items. Total score ranges from 0-45; of which 0-12 is considered no laryngopharengeal reflux, above 13 points for the presence of laryngopharyngeal reflux.

    Days 10-14

  • Laryngopharyngeal reflux diagnosis at baseline

    Video laryngoscopy and assessment of the presence / severity of the symptoms- Reflux finding score. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem. Total score ranges from 0-48; of which 0-6 is considered no laryngopharengeal reflux, above 7 points for the presence of laryngopharyngeal reflux.

    Baseline

  • Laryngopharyngeal reflux diagnosis at Days 10-14.

    Video laryngoscopy and assessment of the presence / severity of the symptoms- Reflux finding score. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem. Total score ranges from 0-48; of which 0-6 is considered no laryngopharengeal reflux, above 7 points for the presence of laryngopharyngeal reflux.

    Days 10-14

  • Test - retest reliability of the RSI questtionaire

    Test - retest reliability of the RSI questtionaire at Days 10-14. Test-retest reliability coefficients vary between 0 and 1, where: 1 : perfect reliability, 0.9: excellent reliability, 0.8 \< 0.9: good reliability, 0.7 \< 0.8: acceptable reliability, 0.6 \< 0.7: questionable reliability, 0.5 \< 0.6: poor reliability, \< 0.5: unacceptable reliability, 0: no reliability. On this scale, a correlation of .9(90%) would indicate a very high correlation (good reliability) and a value of 10% a very low one (poor reliability).

    Days 10-14

  • Test - retest reliability of the RFS

    Test - retest reliability of the RFS questtionaire at Days 10-14. Test-retest reliability coefficients vary between 0 and 1, where: 1 : perfect reliability, 0.9: excellent reliability, 0.8 \< 0.9: good reliability, 0.7 \< 0.8: acceptable reliability, 0.6 \< 0.7: questionable reliability, 0.5 \< 0.6: poor reliability, \< 0.5: unacceptable reliability, 0: no reliability. On this scale, a correlation of .9(90%) would indicate a very high correlation (good reliability) and a value of 10% a very low one (poor reliability).

    Days 10-14

Study Arms (2)

Laryngopharegeal reflux symptoms patients

patients with symptoms of laryngopharyngeal reflux detected at an outpatient appointment with an ENT doctor

Other: Reflux Symptom Index Inventory (diagnostic survey)Other: Reflux finding score

Asymptomatic laryngopharegeal reflux patients

patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist

Other: Reflux Symptom Index Inventory (diagnostic survey)

Interventions

Kazakh versions of the Reflux Symptom Index Inventory will be filled patients

Also known as: RSI
Asymptomatic laryngopharegeal reflux patientsLaryngopharegeal reflux symptoms patients

laryngoscopy with a score RFS

Also known as: RFS
Laryngopharegeal reflux symptoms patients

Eligibility Criteria

Age18 Years - 74 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult female patients between 18 to 74 years of age with a laryngopharengeal symptoms and patients without symptoms of laryngopharyngeal reflux who applied for an appointment with an otorhinolaryngologist/

You may qualify if:

  • Patient's informed consent;
  • Age: 18-74 years old;
  • No serious somatic diseases;
  • Patients with complaints of sore throat, coughing, burning sensation in the throat, coughing, frequent sore throat, difficulty swallowing, lump in the throat, foreign body feeling in the throat, voice changes, heartburn and belching;
  • Diagnosis: Chronic pharyngitis;
  • Chronic laryngitis.

You may not qualify if:

  • Disagreement to participate in scientific research;
  • Age: under 18 and over 74;
  • Severe somatic diseases, organic lesions of the gastrointestinal tract and ENT organs;
  • Patients with pulmonary pathologies;
  • Patients with allergic manifestations (chronic or allergic rhinosinusitis and nasal polyposis);
  • With diagnoses: Acute respiratory diseases;
  • Patients with general neuralgic disorders;
  • Pregnancy;
  • Benign lesions of the vocal cords;
  • Acid-suppressive therapy within 4 weeks prior to recruitment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

SOS Medical Assistance

Almaty, Kazakhstan

Location

V-ent

Almaty, Kazakhstan

Location

MeSH Terms

Conditions

Gastroesophageal RefluxLaryngopharyngeal RefluxLaryngitis

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesLaryngeal DiseasesRespiratory Tract DiseasesRespiratory Tract InfectionsInfectionsOtorhinolaryngologic Diseases

Study Officials

  • Nukusbekova

    Doctor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2022

First Posted

March 25, 2022

Study Start

March 1, 2020

Primary Completion

February 15, 2022

Study Completion

February 16, 2022

Last Updated

May 23, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will share

Non-identifiable IPD will be shared upon request with all required information

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
The data will be available upon completion of the study primary analysis
Access Criteria
Only people with access will be able to see the data

Locations